Literature DB >> 1640190

Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B.

I M Nilsson1, E Berntorp, T Löfqvist, H Pettersson.   

Abstract

In Sweden, prophylactic treatment of boys with severe haemophilia has been practised since 1958 in an attempt to convert the disease from a severe to a milder form. The present study population consisted of 60 severe haemophiliacs (52 A, 8 B), aged 3-32 years. Treatment is started when the boys are 1-2 years of age, the regimens used being 24-40 IU F VIII kg-1 three times weekly in haemophilia-A cases (i.e. greater than 2000 IU kg-1 annually) and 25-40 IU F IX kg-1 twice weekly in haemophilia-B cases. The orthopaedic and radiological joint scores (maximum scores of 90 and 78, respectively) are evaluated as recommended by the World Federation of Haemophilia. Of those subjects aged 3-17 years, 29 out of 35 individuals had joint scores of zero. The oldest group had only minor joint defects. The VIII:C and IX:C concentrations had usually not fallen below 1% of normal. All 60 patients are able to lead normal lives. In conclusion, it appears to be possible to prevent haemophilic arthropathy by giving effective continuous prophylaxis from an early age, and preventing the VIII:C or IX:C concentration from falling below 1% of normal.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1640190     DOI: 10.1111/j.1365-2796.1992.tb00546.x

Source DB:  PubMed          Journal:  J Intern Med        ISSN: 0954-6820            Impact factor:   8.989


  118 in total

1.  Assessment of health-related quality-of-life in males with Anderson Fabry Disease before therapeutic intervention.

Authors:  A H Miners; A Holmes; L Sherr; C Jenkinson; K D MacDermot
Journal:  Qual Life Res       Date:  2002-03       Impact factor: 4.147

2.  Rationale for a randomized controlled trial comparing two prophylaxis regimens in adults with severe hemophilia A: the Hemophilia Adult Prophylaxis Trial.

Authors:  Margaret V Ragni
Journal:  Expert Rev Hematol       Date:  2011-10       Impact factor: 2.929

3.  Cell phones and landlines: the impact of gene therapy on the cost and availability of treatment for hemophilia.

Authors:  Katherine A High; Mark W Skinner
Journal:  Mol Ther       Date:  2011-10       Impact factor: 11.454

4.  Population pharmacokinetics of plasma-derived factor IX in adult patients with haemophilia B: implications for dosing in prophylaxis.

Authors:  Sven Björkman; Victor Ahlén
Journal:  Eur J Clin Pharmacol       Date:  2012-01-27       Impact factor: 2.953

5.  [Prophylactic treatment with low- and intermediate-dose factor VIII in children with severe hemophilia A: comprehensive evaluation of joint outcomes and correlation analysis].

Authors:  Jin-Mu Zhuang; Xue-Yan Sun; Xuan Zhou; Zhu-Qin Liu; Jing Sun
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2018-04-20

6.  Optimized human factor IX expression cassettes for hepatic-directed gene therapy of hemophilia B.

Authors:  Ru Zhang; Qiang Wang; Lin Zhang; Saijuan Chen
Journal:  Front Med       Date:  2015-02-07       Impact factor: 4.592

7.  Need for Prophylactic Treatment in Adult Haemophilia A Patients.

Authors:  Berthold Siegmund; Heinrich Richter; Hartmut Pollmann
Journal:  Transfus Med Hemother       Date:  2009-07-10       Impact factor: 3.747

8.  Prevalence of clinical hip abnormalities in haemophilia A and B: an analysis of the UDC database.

Authors:  D Kelly; Q C Zhang; J M Soucie; M Manco-Johnson; D Dimichele
Journal:  Haemophilia       Date:  2012-12-17       Impact factor: 4.287

9.  Clinical and functional evaluation of the joint status of hemophiliac adults at a Brazilian blood center.

Authors:  Adriana Aparecida Ferreira; Maria Teresa Bustamante-Teixeira; Isabel Cristina Gonçalves Leite; Camila Soares Lima Corrêa; Daniela de Oliveira Werneck Rodrigues; Danielle Teles da Cruz
Journal:  Rev Bras Hematol Hemoter       Date:  2013

10.  Outcomes of 1.8-3.0 mm incision phacoemulsification combined with trabeculectomy for primary angle-closure glaucoma with cataract.

Authors:  Qing Wang; Zheng-Xuan Jiang; Rong-Feng Liao
Journal:  Int J Ophthalmol       Date:  2020-02-18       Impact factor: 1.779

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.